Objectives: Fluoroquinolones are commonly believed to exhibit concentration-dependent killing, but time -kill studies have revealed that fluoroquinolone activity could be a complex combination of concentrationdependent and -independent killing. We had previously developed a mathematical modelling framework to describe the dynamics of bacterial populations under the effect of antimicrobials, which could facilitate the design of optimal dosing regimens. Our objective was to extend the framework to describe the effect of fluoroquinolones on heterogeneous populations of Escherichia coli and Staphylococcus aureus.
Introduction
The problem of bacterial resistance against antimicrobials has reached alarming proportions in recent decades. Evidence suggests that resistance development could be correlated to the use of suboptimal dosing regimens, 1 -7 while optimal dosing regimens are associated with a higher likelihood to suppress the development of resistance. However, determining the optimal dosing regimen for a new antimicrobial is not a trivial task, since a large number of control variables can result in different scenarios. Comprehensive and exhaustive evaluation of all possible combinations would involve a lot of resources in preclinical and clinical investigations. As a result, only a restricted number of dosing regimens are usually evaluated experimentally for new antimicrobial candidates. Thus, a purely experimental approach to antimicrobial development is restrictive, in that it may result in inefficiency or missed opportunities. Mathematical modelling can be a useful aid in antimicrobial development and use. It can offer valuable guidance towards the design and testing of dosing regimens at various stages of development. This can significantly reduce the number of experiments necessary in pre-clinical and clinical investigations.
In our previous work, we developed a modelling approach to characterize the effect of antimicrobials on heterogeneous bacterial populations. 8 In addition, we developed a modelling framework that can predict the efficacy of different dosing regimens. 9 So far, the modelling approach has been validated on only selective drug -bacteria combinations and has been found to be reasonably accurate. To ensure the robustness of the approach (so that it can be used with confidence in guiding the design of clinical trials), it is necessary to evaluate it for a broader range of drug-bacteria combinations. The objective of this study was to evaluate the performance of the modelling approach on predicting the impact of quinolone (moxifloxacin and levofloxacin) exposures on resistance development in Gram-positive (Staphylococcus aureus) and Gram-negative (Escherichia coli) bacteria.
Materials and methods

Antimicrobial agents
Moxifloxacin powder was provided by Bayer Pharmaceuticals (West Haven, CT, USA) and levofloxacin powder was purchased from Waterstone Technologies (Carmel, IN, USA). A stock solution of each antimicrobial agent in sterile water was prepared, aliquotted and stored at 2708C. Prior to each experiment, an aliquot of the agent was thawed and diluted to the desired concentrations with cation-adjusted Mueller-Hinton broth (Ca-MHB; BBL, Sparks, MD, USA) or sterile water.
Microorganisms
Two standard wild-type microorganisms were used in the study: E. coli MG1655 and S. aureus ATCC 29213 (ATCC, Rockville, MD, USA). The bacteria were stored at 2708C in Protect w (Key Scientific Products, Round Rock, TX, USA) storage vials. Fresh isolates were subcultured twice on 5% blood agar plates (Hardy Diagnostics, Santa Maria, CA, USA) for 24 h at 358C prior to each experiment.
Susceptibility studies
MIC was determined in Ca-MHB using a modified macrobroth dilution method as described by the CLSI. 10 The final concentration of bacteria in each macrobroth dilution tube was 5×10 5 cfu/mL of Ca-MHB. Serial 2-fold dilutions of drugs were used. The MIC was defined as the lowest concentration of drug that resulted in no visible growth after 24 h of incubation at 358C in ambient air. The studies were conducted in duplicate and repeated at least once on a separate day.
Mutation frequency
Suspensions of E. coli MG1655 and S. aureus ATCC 29213 were allowed to grow overnight. The suspensions were diluted serially (10×) and plated onto drug-free Mueller-Hinton agar (MHA) plates (Hardy Diagnostics, Santa Maria, CA, USA) and MHA supplemented with 3× MIC of moxifloxacin (for E. coli) or levofloxacin (for S. aureus), respectively. The media plates were incubated for up to 72 h at 358C. Colonies were counted and the mutation frequency of resistance was determined by dividing the bacterial burden on drug-supplemented plates by the bacterial burden on drug-free plates. The studies were conducted three times on separate days.
Time -kill studies
Time-kill studies were performed in 20 mL, using inocula of 1×10 8 cfu/mL at baseline for E. 
Mathematical modelling
For each bacterium, all time-kill profiles were modelled collectively to derive a model fit and model parameter estimates. Briefly, the rate of change of bacteria over time was expressed as the difference between the intrinsic bacterial growth rate and the (sigmoidal) kill rate (provided by the antimicrobial agent). In both time-kill datasets, a biphasic killing profile was observed. Initially there was a rapid decline in the bacterial burden, followed by a much more gradual reduction. This feature prompted the need for different maximal kill rates for the initial phase and the latter phase, namely K k and K b , respectively. Similarly, the concentrations needed to achieve half the maximal kill rates were different for both phases, namely C 50 and C 50b . The decline in kill rate and regrowth over time was attributed to adaptation, expressed by a coefficient, A. Several hierarchical model candidates (using identical maximal kill rates, concentration-dependent adaptation, etc.) were evaluated. The mathematical structure of the final population dynamics model is as shown in Figure 1 . The parameter estimation process involved two steps. The intrinsic bacterial growth rate (K g ) and maximal bacterial population size (N max -to account for contact inhibition) were first derived from placebo control experiments. Using these fixed growth parameter estimates, the parameter values in the killing function were subsequently derived using data from all active treatment experiments simultaneously. All modelling was performed with MATLAB version 7.5 (The MathWorks, Inc., Natick, MA, USA). The MATLAB differential equation solver ode45 was used together with fmincon (a constrained minimization function) for optimization.
Computer model prediction of microbial response
Using the best-fit model parameter values derived, the qualitative microbial response (with respect to whether resistance would develop over time) to various clinically relevant drug exposures was predicted. Briefly, the average kill rate (D) of different dosing regimens against the most resistant population was derived as shown previously 9, 11 and compared with the growth rate (K g ) of the bacterial population. Resistance development over time is anticipated if D/K g , 1. The pharmacokinetic parameters of moxifloxacin and levofloxacin were derived from previous studies.
12 -14 All simulations were performed with MATLAB version 7.5 (The MathWorks, Inc., Natick, MA, USA) and Mathematica 6.0 (Wolfram Research, Inc., Champaign, IL, USA).
Experimental validation
The computer simulations were compared with experimental data from an in vitro hollow-fibre infection model with selected antimicrobial agent exposures for up to 120 h. The experimental set-up has been described elsewhere. 15 A human-like elimination half-life ( 12 h for Bhagunde et al. moxifloxacin 12,14 and 5 -7 h for levofloxacin 13 ) was simulated in the infection models. Serial samples were obtained from a circulatory loop of the infection models over time, to ascertain the simulated pharmacokinetic exposures by a validated HPLC assay. 16, 17 In addition, serial samples were obtained at baseline, 4 h, 8 h and daily (pre-dose) in duplicate from each hollow-fibre system for quantitative culture, as described above (to define the effects of various drug exposures on the bacterial population). In addition to the total bacterial population, subpopulations with reduced susceptibility were quantified by culturing samples on cation-adjusted MHA plates supplemented with the exposed agent (moxifloxacin or levofloxacin) at a concentration of 3× MIC. The medium plates were incubated at 358C for up to 24 h (total population) and 72 h (subpopulations with reduced susceptibility), and the bacterial density of each sample was enumerated visually. Susceptibilities of the isolates recovered from the drug-supplemented medium plates at the end of the experiments to the exposed agent were repeated to confirm the emergence of resistance. The mechanism of resistance was confirmed by PCR of the quinolone resistance-determining regions (QRDRs) of the gyrA and parC (or grlA in S. aureus) genes of the resistant isolates. 16, 17 Accounting for biofitness
In the mathematical modelling analysis, the growth rate constant was assumed to be the same for all bacteria, regardless of fluoroquinolone susceptibility. To support this assumption, parallel time-growth experiments were performed on the parent (susceptible) and a randomly selected daughter (resistant) strain which has undergone molecular investigations. A baseline inoculum of 1×10 5 cfu/mL was used. Serial time samples (baseline, and 1, 2, 3, 4, 6, 8 and 24 h) were taken in triplicate. The viable bacterial burden for each time sample was obtained by quantitative culture, as described above. The growth function of the mathematical model ( Figure 1 ) was fitted to the bacterial burden -time profiles to derive the growth rates, and they were compared using Student's t-test.
Amplification of resistance
To substantiate resistance amplification as a plausible cause of regrowth, levofloxacin time-kill experiments (control, 0.125 mg/L and 0.25 mg/L) were repeated, as described above. After 24 h, each suspension (10 mL) was washed, diluted and plated onto drug-free MHA and MHA supplemented with 3× MIC of levofloxacin. The proportion of the bacterial population with reduced susceptibility was determined as described above and compared.
Results
Susceptibility studies and mutation frequency
The MIC of moxifloxacin for the E. coli MG1655 isolate and of levofloxacin for the S. aureus ATCC 29213 isolate were found to be 0.0625 and 0.25 mg/L, respectively. The mutation frequency of moxifloxacin/levofloxacin resistance (at 3× MIC) C 50 -concentration to achieve 50% maximal kill rate of the initial population C 50b -concentration to achieve 50% maximal kill rate of the most resistant population
H -sigmoidicity constant for bacterial population
A -adaptation function Figure 1 . Bacterial growth dynamics model and various model parameters.
Modelling of fluoroquinolones 1081 JAC was 0.5 -3×10 29 in E. coli MG1655 and 2-8×10 29 in S. aureus ATCC 29213. Based on these mutation frequencies, pre-existing mutants could be present and the baseline inocula used in time -kill/hollow-fibre model studies were therefore deemed to be heterogeneous.
Time -kill studies
In both sets of time -kill studies, a biphasic killing profile was observed. These bacterial burden -time profiles were reasonably described by the model. Data from the time -kill studies and model fits to the data are shown as overlay plots in Figure 2 . The correlation plots are shown in Figure 3 . The estimates of the best-fit model parameters are shown in Table 1 .
Computer simulation and experimental validation
Using the best-fit model parameter estimates, predictions were made relating to the emergence of resistance as a function of daily dose and dosing interval. The corresponding values of AUC 24 /MIC ratios examined ranged from 26 to 345. In all cases, there was a significant initial reduction in the bacterial burden. Regrowth and resistance emergence was subsequently observed with suboptimal dosing regimens, but not with optimal regimens. For both bacteria, the mathematical model predictions were in general agreement with the experimental results. A moxifloxacin dose of 85 mg once daily (every 24 h) was predicted to be necessary to suppress E. coli resistance.
We have previously shown that a simulated dose of 80 mg of moxifloxacin once daily resulted in the emergence of resistance over time, whereas resistance suppression was observed with 120 mg once daily. 16 A more comprehensive analysis was performed for levofloxacin, as shown in Figure 4 . Based on the model predictions, a dose of 166 mg twice daily and 487 mg once daily was necessary to suppress the emergence of resistance. A total of eight different and escalating dosing regimens were used to experimentally verify the predictive performance of the model. The predictive performance of the model is as shown in Figure 4 . Typical Bhagunde et al.
pharmacokinetic profiles and bacterial responses observed are as shown in Figure 5 . Overall, the model prediction was reasonably reliable in predicting resistance emergence in 75% (six out of eight) of the dosing experiments.
Confirmation of resistance
The mechanism of moxifloxacin resistance in E. coli (Ser83Leu substitution in gyrA) has been previously published. 16 Three randomly selected resistant isolates of S. aureus were recovered from the drug-supplemented plates at the end of the experiment, corresponding to 40 mg of levofloxacin every 12 h. Susceptibility studies revealed levofloxacin resistance with a 6-to 8-fold elevation in MIC; subsequent sequencing of QRDRs showed substitution of Ser80Phe in grlA, and no mutation was observed in gyrA. In addition, four resistant isolates were recovered from the drug-supplemented plates from the experiment corresponding to 100 mg of levofloxacin every 24 h. Levofloxacin resistance was observed with a 96-to 128-fold increase in MIC. Sequencing of QRDRs revealed substitution of Ser84Leu in gyrA and Ser80Phe in grlA.
Accounting for biofitness and resistance amplification
For both bacteria, time -growth studies revealed that there was no significant difference in the growth rates between the parent (wild-type) and daughter (resistant) strains. , respectively. This finding was also consistent with our assumption of the presence of pre-existing resistant mutants.
Discussion
Fluoroquinolone pharmacodynamics has been investigated extensively and it is well accepted that fluoroquinolones exhibit concentration-dependent antimicrobial activity. 18, 19 Both AUC/MIC and C max /MIC have been recognized to be the most important pharmacodynamic indices for quinolones. 20 -22 However, the exposure necessary for favourable outcomes may not be the same for different bacteria. A pharmacodynamic study of fluoroquinolones on Streptococcus pneumoniae revealed that an AUC/MIC ratio .33.7 was necessary for clinical and microbiological responses, 23 but a significantly higher AUC/MIC ratio (.125) was necessary against Gram-negative bacteria. 20 Furthermore, significantly different drug exposures were necessary to suppress resistance in S. pneumoniae and Pseudomonas aeruginosa. The feasibility of fluoroquinolones to suppress resistance has also been examined by our group. In vitro studies on the effect of moxifloxacin against a high inoculum of E. coli indicated that a clinical dose .80 mg/day (AUC 24 /MIC .117) was associated with resistance suppression. 16 A more general study reported an inverted-U relationship between fluoroquinolone exposures and resistance amplification; 4 resistance amplification was minimal at low drug exposures, which rose to a peak at intermediate exposures and eventually became negligible again at high enough exposures. Similarly, in vivo studies had demonstrated that resistance emergence in P. aeruginosa and S. pneumoniae could be related to fluoroquinolone exposures. 1, 24 In this work, we modelled the effect of two different fluoroquinolones on both Gram-negative and Gram-positive bacteria. In time -kill studies, the classical concentration-dependent activity of fluoroquinolones was not observed. Instead, a biphasic killing profile was seen. There was concentration-dependent killing during the initial phase (i.e. the rate of bacterial burden reduction could be directly correlated to the drug concentration). However, during the latter phase there seemed to be little or no correlation between a further rate of reduction in the bacterial burden and the concentration of drug. Most of the killing profiles emerged as a bundle towards an asymptote. A similar phenomenon was observed in both Gram-positive and Gram-negative bacteria. Such an observation revealed that fluoroquinolone activity could be a complex combination of concentrationdependent and -independent killing. To describe the population dynamics for both bacteria, an alternative modelling structure rather than the general structure developed previously was necessary. 9 Thus, keeping the key aspects of the previous framework, we developed a model structure that was able to describe the bacterial population dynamics for such complex phenomena. Instead of assuming the presence of two discrete populations, we described a heterogeneous population with an infinite number of subpopulations with different drug susceptibilities. 
Modelling of fluoroquinolones
Under a drug selective pressure, there was a gradual change from one type (concentration dependent) of profile to another (bundling) over time. This is a novel and unique feature of a single population model that we propose. Previous attempts of allowing just the maximum kill rate to vary did not result in satisfactory predictions (data not shown).
We demonstrated that the model was satisfactory to describe the dynamics of the bacterial population under the effect of fluoroquinolones. Furthermore, selective validation showed that the model predictions in the extended time frame (with respect to resistance development) were in reasonable agreement with experiments using clinically relevant drug exposures (i.e. fluctuating concentration over time). In the model, we made an assumption of similar growth rates for all bacteria, regardless of susceptibility. This was later substantiated via time -growth experiments, showing that there was no significant difference between the growth rates of a parent (susceptible) and a daughter (resistant) strain. However, if there was a small biofitness cost associated with resistance, it could have explained the bias we observed in the model predictions. A lower drug exposure than anticipated would be needed to suppress resistance development over time. Additionally, resistance amplification was proposed as a mechanism contributing to bacterial regrowth. This assumption was also supported by our experimental data. Finally, the mechanism of quinolone resistance was also confirmed by relevant molecular studies. We recognized that the biphasic killing profiles in time -kill studies could have been modelled using the non-susceptible persister concept. 25 However, the emergence of resistance observed in hollow-fibre infection models over time would not have been predicted.
An attractive feature of the model presented is that it does not require detailed knowledge of the mechanism of resistance as inputs. Based on data from simple time -kill studies, we were able to make reasonable predictions on the likelihood of resistance development for both the drug-bacteria combinations. This aspect of the model is especially useful in early drug development, since very often little is known about the resistance mechanism for novel entities. In short, our model was validated for two more drug -bacteria combinations, strengthening the robustness of the modelling approach. We also showed how slight changes in the model structure could help to explain the dynamics for different drug-bacteria combinations without a significant loss of predictive performance.
As with all other modelling approaches, there are several limitations in our approach. The model predictions were not 100% in agreement with experimental observations, which could be partly overcome by quantifying the uncertainty in model parameters and model predictions. To improve the predictive performance of the model, the physiological state of the bacterial cells might have to be taken into account (e.g. using molecular dyes for active metabolism). Furthermore, the model did not address the effect of the immune system in vivo, which is currently under investigation.
In conclusion, we extended the modelling framework to describe the activity of fluoroquinolones against both Grampositive and Gram-negative bacteria, which allow optimal dosing regimens to be designed. Our modelling approach is a promising decision support tool to guide the investigation of new drug candidates. Further in vivo investigations are ongoing to further extend our modelling approach.
